
    
      Subjects who have given informed consent and determined to be eligible at screening will be
      randomized in a 1:1 ratio to DEXTENZA (placed once in the lower punctum) or the use of
      topical Prednisolone acetate 1% drops (four times daily). They will be observed for a period
      of 3-months for both pain and inflammation of the eye.
    
  